Bicoll prepares its market entry to Japan with the support of two globally experienced European life science clusters BioM and Biocat
Planegg / Martinsried (Germany), May 15, 2018 – Bicoll Group was selected for this exclusive training programme, together with nine (9) other European-based companies from five (5) different countries. It will take part in Start.Smart.Japan developed by BioM, the network organization for the biotechnology sector in Munich and in Bavaria, commissioned by the Bavarian Ministry of Economic Affairs. The focus is on developing partnerships with Japanese companies or academia. The project includes both cultural training as well as sector-specific business environment training. Bicoll already collaborates with innovative US and European biotechs/big pharma and academia. Bicoll competences cover the fasted small molecule drug discovery approach. Bicoll wants to bring in its nearly 20 years of competence in the field of Drug Discovery directly to Japanese partners.
Japan is an attractive research-oriented pharmaceutical market focused on the development of new drugs and technologies in the field of the biotechnology and pharmaceuticals. Since 2017, Bicoll is deeply involved in the InnoMuNiCH initiative (German-Japanese cooperation for the advancement of biomedical innovations). InnoMuNiCH aims to increase global innovations in the biopharmaceutical industry and to pool together German and Japanese expertise in research and development.
Bicoll Plant ProfilesTM is a readily available product, which speeds up the drug development process and brings it to animal tests within nine months (S. Helleboid et al. Journal of Biomolecular Screening, 2014, 19, 399-406). Dr. Kai Lamottke, Managing Director of Bicoll, points out: “It is very impressive, what you can achieve with our skill set of competencies in collaborations. Just recently we could provide the expertise to a partner of Bicoll, who could bring their early research project to consumers within three years. Not having access to this approach might be disadvantageous for our Japanese collaborators; this we want to change.” Bicoll is looking forward to providing this opportunity also to Japanese companies to get access to the most successful source for new pharmaceuticals.
Bicoll is a biopharmaceutical company, offering pre-clinical support in the area of drug discovery from natural products and medicinal chemistry. Dedicated to the discovery and optimization of the highest quality lead compounds, Bicoll provides an efficient, multi-disciplinary approach to drug discovery. With outstanding expertise in high tech natural product chemistry and validated experience in medicinal chemistry, Bicoll increases quality and quantity of the drug discovery pipeline of its partner’s candidates portfolio.
Bicoll Group provides its services to a number of international clients of various fields of interest, e.g. pharmaceutical and agrochemical industry. Bicoll comprises two legal entities: Bicoll GmbH in Planegg / Martinsried, Germany and its 100% daughter company Bicoll Biotechnology (Shanghai) Co. Ltd., P.R. China. Technology development, cooperation management and marketing are functions in Martinsried, while facilities for research and development are located in Shanghai. Currently Bicoll employs 40 people at both locations. More at www.bicoll-group.com and LinkedIn.
Start.Smart.Japan is an exclusive, high quality training course that provides a starter kit for executives of European life sciences small and medium size enterprises (SMEs), helping them to optimize and accelerate their market entry in Japan. The training was developed by BioM and is sector-specific. It targets the challenging Japanese business environment: regulatory and reimbursement regulations for health products/services, access to agents and distributors addressing appropriate customer networks, access to funding and financing opportunities, language and cultural complexities, different business conventions, understanding of market needs and competition.
InnoMuNiCH stands for “Innovations through Munich-Nippon Cooperations in Healthcare”. The project is funded by the BMBF and managed by BioM. InnoMuNiCH links pharmaceutical companies, research groups and biomedical SMEs from Japan with cooperation partners in Munich, Bavaria and beyond. The project provides a platform for German-Japanese cooperation to initiate and foster bi-national research and development projects. Both, German and Japanese players will profit from this cooperation between partners on equal terms.
About EIT Health
138 partners from 17 European countries make EIT Health one of the worldwide biggest health initiatives. The aim of the European Institute of Innovation and Technology Health (EIT Health) is to promote entrepreneurship and innovation in the areas of “Healthy Living and Active Aging” in order to improve the quality of life, medical care and healthcare across Europe.
Media contact of Bicoll
Maria Lamottke, public relations manager
Tel.: 0049 89820 10630
Follow us @BicollGroup